Prof Yung-Jue Bang, MDa,*, Rui-Hua Xu, MDb, Keisho Chin, MDc, Keun-Wook Lee, MDd, Prof Se Hoon Park, MDe, Prof Sun Young Rha, MDf, Lin Shen, MDg, Shukui Qin, MDh, Prof Nong Xu, MDi, Seock-Ah Im, MDa, Gershon Locker, MDj, Phil Rowe, MSck, Xiaojin Shi, MDl, Darren Hodgson, PhDk, Yu-Zhen Liu, MDm, Narikazu Boku, MDn
a Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
b Sun Yat-sen University Cancer Center, Guangzhou, China
c The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
d Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, South Korea
e Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea
f Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
g Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
h Nanjing Bayi Hospital, Nanjing, China
i The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
j AstraZeneca, Gaithersburg, MD, USA
k AstraZeneca, Macclesfield, UK
l AstraZeneca, Shanghai, China
m AstraZeneca, Cambridge, UK
n National Cancer Center Hospital, Tokyo, Japan
*Correspondence to: Prof Yung-Jue Bang, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongro-gu, Seoul 03080, South Korea